New drug aims to shrink liver fat and prevent scarring in fatty liver disease

NCT ID NCT07024212

Ongoing Disease control Sponsor: Zhejiang Doer Biologics Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jul 08, 2026 · Updated 3 times

Summary

This Phase II trial tests an injection called DR10624 in 110 adults with fatty liver disease (MASLD) who are at high risk of liver fibrosis (scarring). The study is split into two parts: Part 1 checks if the drug reduces liver fat and fibrosis risk, while Part 2 focuses on safety in a related condition. Participants are randomly assigned to receive either DR10624 or a placebo, and neither they nor their doctors know which they get.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: DR10624 injection (a drug being tested to reduce liver fat and fibrosis)
What this could lead to: If successful, this could point toward a new treatment option for people with fatty liver disease who are at high risk of liver scarring.
What could go wrong: This is an early Phase II trial with only 110 participants, so results may not apply to everyone. The drug may not work better than placebo, and side effects are still being studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MASLD are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metabolic dysfunction and alcohol associated liver disease metabolic dysfunction-associated steatotic liver disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MASLD

Contacts and locations

Locations

Nanjing Gulou Hospital

Nanjing, China
Prince of Wales Hospital, The Chinese University of Hong Kong

Hong Kong, Hong Kong, Hong Kong
The Affiliated Hospital of Hangzhou Normal University

Hangzhou, Zhejiang, China
The First Hospital of Jilin University

Changchun, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.